Oxford Asset Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Oxford Asset Management’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-12,249	Closed	-$603K	–	1984
2018 Q2	$603K	Sell	12,249 -35,534	-74%	-$1.34M	0.01%	1267
2018 Q1	$1.47M	Buy	47,783 +13,702	+40%	+$380K	0.03%	743
2017 Q4	$642K	Buy	34,081 +1,900	+6%	+$29.5K	0.01%	1106
2017 Q3	$365K	Buy	+32,181	New	+$186K	0.01%	1294
2016 Q2	–	Sell	-58,158	Closed	-$1.25M	–	896
2016 Q1	$1.25M	Buy	58,158 +30,769	+112%	+$688K	0.04%	464
2015 Q4	$855K	Buy	+27,389	New	+$967K	0.02%	569

Other funds holding MRTX

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Oxford Asset Management's MRTX Position: Q3 2018 in Review

Oxford Asset Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q3 2018, closing a stake of 12,249 shares — an estimated $603K sold.

Oxford Asset Management first reported a position in MRTX in Q4 2015 and held it in 6 quarters. The position peaked at $1.47M in Q1 2018. 125 funds tracked by Wall St. Rank hold MRTX as of Q3 2018.

Oxford Asset Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q3 2018 after selling out during the quarter.
Oxford Asset Management sold 12,249 Mirati Therapeutics, Inc. Common Stock shares in Q3 2018, an estimated $603K.
Oxford Asset Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2015 and held it in 6 quarters.
Oxford Asset Management's Mirati Therapeutics, Inc. Common Stock position peaked at $1.47M in Q1 2018.
125 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q3 2018.

Based on Oxford Asset Management's 13F filing for Q3 2018, filed 14 Nov 2018.